<DOC>
	<DOCNO>NCT00434369</DOCNO>
	<brief_summary>A multi-center , open-label , single-arm Phase II trial assess efficacy safety weekly bolus infusion 5-fluorouracil combined CoFactor ( 5-10 methylenetetrahydrofolate ) advance breast cancer patient fail anthracycline taxane chemotherapy regimen .</brief_summary>
	<brief_title>5-Fluorouracil Combined With CoFactor ( 5-10 Methylenetetrahydrofolate ) Treating Advanced Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<criteria>Signed informed consent . Women histologically/cytologically proven diagnosis advance adenocarcinoma breast . Measurable disease . At least one unidimensionally measurable nonbony lesion diameter &gt; =10 mm use spiral CT scan ( use spiral CT must document medical record use consistently throughout study ) &gt; = 20 mm use conventional CT MRI scan outside irradiate area accord RECIST criterion . Patients fail prior anthracycline taxane derivative chemotherapy regimen . Anthrocycline Taxane failure definition define protocol . No two prior chemotherapy regimen advance disease . Performance status ( ECOG ) &lt; = 2 Karnofsky &gt; = 70 Age &gt; = 18 year . Life expectancy &gt; = 12 week . Adequate organ function show follow : 1 . WBCs &gt; = 3.0 x 109/L , absolute neutrophil count ( ANC ) &gt; = 1.5 x 109/L , platelet &gt; = 100 x 109/L , hemoglobin &gt; = 9 g/dL 2 . Bilirubin &lt; = 1.25 x upper limit normal ( ULN ) , aspartate aminotransferase ( AST alanine aminotransferase ( ALT ) , = 3 x ULN ( &lt; = 5 x ULN case liver metastasis ) 3 . Serum calcium within normal limit 4 . Serum albumin within normal range study site 5 . Creatinine clearance &gt; = 60 mL/min ( Cockroft Gault ) 6 . Left ventricular ejection fraction ( LVEF ) within normal limit show echocardiography scintigraphy ( multiplegated acquisition scan ) . Patients childbearing potential must use medically acceptable contraception 4 week start study treatment 4 month study treatment completion . Patients childbearing potential must negative pregnancy test result within 7 day prior study treatment initiation . Patients parenchymal brain metastasis must either adequately control follow resection complete appropriate radiation therapy receive stable corticosteroid dose prior study entry . Patients leptomeningeal involvement include study . Her2/neu positive tumor ( 2+ 3+ ) . Pregnancy lactation Systemic cytotoxic anticancer therapy within &lt; =4 week study entry , 6 week systemic therapy contain nitrosourea mitomycin C. Hormonal anticancer treatment must ongoing , must discontinue &gt; 3 month study entry . Prior 5FU and/or capecitabinebased palliative chemotherapy . Extensive prior radiotherapy affect 30 % bone marrow reserve , bone marrow / stem cell transplantation . Participation clinical study nonapproved experimental agent procedure within &lt; =4 week study entry . History malignancy , unless cure patient diseasefree &gt; =2 year . Patients history cervical carcinoma situ cure stage I cervical cancer , epidermal basal cell skin cancer , may eligible enrollment discussion sponsor . Previous unexpected reaction fluoropyrimidines , without documented deficiency dihydropyrimidine dehydrogenase , know hypersensitivity 5FU . Psychologic , familial , sociologic geographic condition permit compliance study protocol and/or study . Significant cardiac disease , include symptomatic ventricular arrhythmia , congestive heart failure , myocardial infarction within 12 month study entry . Concomitant treatment experimental drug anticancer drug , except hormone therapy bisphosphonates .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>